Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
N/A
1(33.3%)
3Total
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04704830Phase 3Active Not Recruiting

R21/Matrix-M in African Children Against Clinical Malaria

Role: collaborator

NCT03967054Phase 3Completed

Repeat Ivermectin Mass Drug Administrations for MALaria Control II

Role: collaborator

NCT01210040Not ApplicableCompleted

Long-term Iron Supplements and Malaria Risk in Early Pregnancy: a Randomized Controlled Trial

Role: collaborator

All 3 trials loaded